[ad_1]
The first results From the observational study, CaReMe, based on registry data especially from Sweden for the years 2007 to 2016, has now been presented. The study followed 645,180 people with type 2 diabetes who had never had an established cardiovascular disease. The result shows that 17% had developed cardiovascular complications at follow-up after an average of 4.3 years. For more than half of these people, cardiorenal disease, ie renal and / or cardiac failure, was the first most common cardiovascular complication.
In addition, the results of the study show that the risk of developing heart failure in a person with type 2 diabetes (26%) as the first cardiovascular event is twice as common as the risk of heart attack. (13%).
– Risk assessment for our people with type 2 diabetes is important for choosing a treatment strategy and treatment and for reducing complications over time. Preventive measures and improved treatment have reduced the risk of complications and deaths in myocardial infarction, but the risk of heart failure is a persistent problem for this group of patients, comments Anna Norhammar, Associate Professor of Cardiology at Karolinska Institutet, co-author and member of the scientific committee of the CaReMe study.
The study shows that The development of renal failure and heart failure is both the first of the hospital complications and the most serious of the cardiovascular complications of type 2 diabetes. Among type 2 diabetics who have developed cardiovascular disease (17%) in just over four years, renal and / or cardiac failure was the most common (59%), then kidney failure (33%) separately, followed closely by l & # 39; Heart failure (26%). In addition, strokes were the first cardiovascular event on 18%, myocardial infarction 13% and peripheral arterial disease 10% of those who developed a complication during follow-up.
The study results also show how the first respective cardiovascular event affects survival, where the combined development of renal and cardiac insufficiency is the most affected survival, followed by heart failure then d & # 39; Kidney failure separately.
|
About the study: CaReMe is the first major international observational study of its kind and involves more than one million people with type 2 diabetes. The study maps the presence of cardiovascular risk and how early cardiovascular events affect survival. people with type 2 diabetes. Cardiovascular complications have been defined as a cardiorenal disease, that is, renal failure and / or heart failure, myocardial infarction, stroke, peripheral arterial disease. Researchers from the University of Uppsala and the Karolinska Institutet collaborate with AstraZeneca on CaReMe from a Swedish perspective. |
[ad_2]
Source link
